MedTrace Logo

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

NCT01515345 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1008

Last updated 2017-04-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer).

Conditions

  • Platelet Inhibition
  • Coronary Stent Implantation

Interventions

DRUG

prasugrel or ticagrelor

prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month

DRUG

Clopidogrel

clopidogrel 75mg od for 12 month

Sponsors & Collaborators

  • Kaiser Franz Josef Hospital

    lead OTHER

Principal Investigators

  • Guenter Christ, MD · Kaiser Franz Josef Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01515345 on ClinicalTrials.gov